Fredun Pharmaceuticals (Small Cap - Next Multibagger) Share Target 2025, 2026 To 2035
|
Fredun Pharmaceuticals Limited |
|||
|
Price: ₹747.95 (+1.89%) | ||
| 52 Week Low: ₹650.00 52 Week High: ₹1,054.00 |
|||
| Market Capital: 268.1 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Fredun Pharmaceuticals Share Price Target For 2025
- 1.1.1: Fredun Pharmaceuticals Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Fredun Pharmaceuticals Share Price Target For 2026
- 1.2.1: Fredun Pharmaceuticals Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Fredun Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Fredun Pharmaceuticals Financial Performance
- 3.0.1: Is Fredun Pharmaceuticals A Good Buy For Long Term?
To predict the Fredun Pharmaceuticals's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Fredun Pharmaceuticals Share Price Target For 2025
The line chart displays the monthly closing prices of Fredun Pharmaceuticals with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Fredun Pharmaceuticals shares in 2025, see the table below.
Fredun Pharmaceuticals Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 813.5 (+8.76%) | Price Action: 14 Oct 2024 High |
| 2025 Target 2 | 805.0 (+7.62%) | Price Action: 01 Feb 2024 Low |
| 2025 Target 1 | 797.0 (+6.55%) | Price Action: 08 Feb 2024 Low |
| Current Price | 747.95 | Fredun Pharmaceuticals's share price as of 02 Jan 2025 |
| Stop Loss 1 | 714.0 (-4.54%) | Price Action: 11 Nov 2024 High |
| Stop Loss 2 | 706.85 (-5.5%) | Price Action: 27 Nov 2024 Low |
| Stop Loss 3 | 698.0 (-6.68%) | Price Action: 26 Nov 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Fredun Pharmaceuticals is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹749.24 serves as the nearest technical reference point.
Historical Returns: 3-month: +5.91% | 6-month: -13.33% | 1-year: -10.18%
Fredun Pharmaceuticals Share Price Target For 2026
The line chart displays the monthly closing prices of Fredun Pharmaceuticals with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Fredun Pharmaceuticals shares in 2026, see the table below.
Fredun Pharmaceuticals Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 1161.8 (+55.33%) | Price Action: Chart |
| 2026 Target 2 | 1140.14 (+52.43%) | Price Action: Chart |
| 2026 Target 1 | 1128.85 (+50.92%) | Fibonacci Extension Level 64.90% |
| Current Price | 747.95 | Fredun Pharmaceuticals's share price as of 02 Jan 2025 |
| Stop Loss 1 | 650.0 (-13.1%) | Price Action: Mar 2024 Low |
| Stop Loss 2 | 637.0 (-14.84%) | Price Action: Sep 2021 High |
| Stop Loss 3 | 625.53 (-16.37%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Fredun Pharmaceuticals is currently trading near its 52-week low of ₹650, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: -10.18% | 3-year: -32.56% | 5-year: +267%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Fredun Pharmaceuticals Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹747.95 | ||
| 2025 | ₹873.84 | +16.83% | ₹886.95 |
| 2026 | ₹1,351.10 | +54.61% | ₹1,371.37 |
| 2027 | ₹1,777.42 | +31.55% | ₹1,804.08 |
| 2028 | ₹3,147.67 | +77.09% | ₹3,194.89 |
| 2029 | ₹5,012.37 | +59.24% | ₹5,087.56 |
| 2030 | ₹5,144.99 | +2.64% | ₹5,222.16 |
| 2031 | ₹5,329.06 | +3.57% | ₹5,409.00 |
| 2032 | ₹5,610.80 | +5.28% | ₹5,694.96 |
| 2033 | ₹6,204.66 | +10.58% | ₹6,297.73 |
| 2034 | ₹6,870.88 | +10.73% | ₹6,973.94 |
| 2035 | ₹8,566.58 | +24.67% | ₹8,695.08 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Fredun Pharmaceuticals Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 268.1 Crore | Market valuation of Fredun Pharmaceuticals's shares. |
| Revenue (TTM) | 346.57 Crore | Total revenue generated by Fredun Pharmaceuticals over the past twelve months. |
| Net Income (TTM) | +15.62 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +9.8% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +20.66% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+37.86% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
1.04 | Company's total debt divided by total shareholder equity. |
| Total Debt | 137.15 Crore | Sum of Fredun Pharmaceuticals's current & long-term financial obligations. |
Is Fredun Pharmaceuticals A Good Buy For Long Term?
Fredun Pharmaceuticals, a small-cap stock with a market capitalization of ₹268.1 crore, presents a mixed picture for long-term investors. While its revenue (₹346.57 crore TTM) and net profit (₹15.62 crore TTM) are positive, a significant debt of ₹137.15 crore (Q2 2024-25) raises concerns. Although the past 5-year returns (99.34%) are impressive, recent performance is weak (-22.65% YTD, -28.36% over 6 months). Considering the substantial debt and negative recent returns, Fredun Pharmaceuticals is currently a not a good buy for long-term investors. Further due diligence is strongly recommended.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
